Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
Summary
Triastek co-founder and CEO Dr. Senping Cheng said, "We appreciate the support from Matrix Partners China, CPE, SSICC and our existing shareholders. It is Triasteks unrelenting goal to develop cutting-edge therapeutics that address unmet patient needs, revolutionize pharmaceutical manufacturing and improve human health. We are optimistic that in the future, through its technology platform, Triastek will continue to bring forth innovative drugs for patients with unmet clinical needs. " We firmly believe that Triasteks 3D printing pharmaceutical technology will be a platform with global influence and become a development and manufacturing leader for the whole industry. The companys second product T20 received positive pre-IND feedback from the US FDA in March 2021 and an IND application submission for T20 is planned for the end of this year.